Clinical Trial Update: BR101 in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating BR101 in patients with relapsed/refractory multiple myeloma. The study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BR101

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Multiple Myeloma (MM) | Phase 1 | Status: NOT_YET_RECRUITING